Respiratory

Biologic therapies targeting eosinophilic inflammation hold promise for COPD management. Realising their benefits will require…

Survivors of severe COVID-19 may exhibit immune dysregulation, characterised by reduced naïve and increased senescent and exhausted T cell…

Interstitial lung diseases (ILD) are a heterogeneous group of chronic disorders leading to progressive lung damage and disability. While…

Fibrotic interstitial lung disease (fibrotic ILD) entails a spectrum of different clinical entities characterised by an irreversible…

Each year, the European Lung Foundation (ELF) recognises outstanding research that advances patient-centred care and promotes lung health…

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the presence…

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of pulmonary…

The following abstract highlights spotlight selected abstracts presented at the European Respiratory Society (ERS) Congress 2024. They…